Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2.
A recombinant replication-defective adenovirus vector that can overexpress the ectodomain of the envelope protein of dengue virus type 2 (NGC strain) has been constructed. This virus was immunogenic in mice and elicited dengue virus type 2 specific B- and T-cell responses. Sera from immunized mice contained neutralizing antibodies that could specifically recognize dengue virus type 2 and neutralize its infectivity in vitro, indicating that this approach has the potential to confer protective immunity. In vitro stimulation of splenocytes (from immunized mice) with dengue virus type 2 resulted in a significant proliferative response accompanied by the production of high levels of gamma interferon but did not show significant changes in interleukin-4 levels. This is suggestive of a Th1-like response (considered to be important in the maturation of cytotoxic T lymphocytes that are essential for the elimination of virus-infected cells). The data show that adenovirus vectors offer a promising alternative strategy for the development of dengue virus vaccines.
Jaiswal
Smita
S
International Centre for Genetic Engineering and Biotechnology, New Delhi 110067, India.
Khanna
Navin
N
Swaminathan
S
S
D000256:Adenoviridae / Q000235:genetics / Q000276:immunology* / Q000502:physiology; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D002460:Cell Line; D006224:Cricetinae; D003673:Defective Viruses / Q000235:genetics / Q000276:immunology* / Q000502:physiology; D003716:Dengue Virus / Q000276:immunology*; D004591:Electrophoresis, Polyacrylamide Gel; D005822:Genetic Vectors; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis; D015847:Interleukin-4 / Q000096:biosynthesis; D051379:Mice; D009500:Neutralization Tests; D014779:Virus Replication
D000914:Antibodies, Viral; D015847:Interleukin-4; D007371:Interferon-gamma